Snapshot from Jul 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Diagnos extends warrant expiry
Business warrant amendment

Diagnos extends warrant expiry

Analysis based on 7 articles · First reported Jul 07, 2026 · Last updated Jul 07, 2026

Sentiment
0
Attention
0
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This minor corporate action is unlikely to have a significant market impact. It provides existing warrant holders additional time to exercise, potentially affecting the company's capital structure if exercised.

healthcare technology
Event Summary

Diagnosis Inc., a Canadian AI-driven health diagnostics company, announced on July 7, 2026, its intention to extend the expiry date of 6,715,369 stock warrants from August 5, 2026 to June 5, 2027. The warrants, issued as part of a non-brokered private placement in February 2025, have an exercise price of C$0.40 per share. The amendment is subject to TSX Venture Exchange approval.

Entities Involved
exch
TSX Venture Exchange
The TSX Venture Exchange must approve the amendment, acting as a regulatory gatekeeper.
Importance 10.0 Sentiment 0.0
per
André Larente
André Larente is the President of Diagnosis and the contact person for the announcement.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.